News
AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...
The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.
Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...
InsideNoVa on MSN10d
AstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobsIn a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...
British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...
On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...
The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...
The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...
Zacks Investment Research on MSN1d
Here's Why Astrazeneca (AZN) is a Strong Momentum StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback